Roche has signed a $1.7 billion agreement with Blueprint Medicines to develop and commercialize Blueprint’s pralesetinib for treatment of patients with RET-altered cancers.

Even in the midst of the COVID-19 pandemic, some drugmakers have continued to impose price hikes, raising the list prices for 42 branded drugs by an average of 3.5 percent in July so far, according to a drug price watchdog.